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Differentiation and protective capacity of virus-specific CD8+ T
cells suggest murine norovirus persistence in an immuneprivileged enteric niche
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SUMMARY

Author Manuscript

Noroviruses can establish chronic infections with active viral shedding in healthy humans but
whether persistence is associated with adaptive immune dysfunction is unknown. We used
genetically engineered strains of mouse norovirus (MNV) to investigate CD8+ T cell
differentiation during chronic infection. We found that chronic infection drove MNV-specific
tissue-resident memory (Trm) CD8+ T cells to a differentiation state resembling inflationary
effector responses against latent cytomegalovirus with only limited evidence of exhaustion. These
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MNV-specific Trm cells remained highly functional yet appeared ignorant of ongoing viral
replication. Pre-existing MNV-specific Trm cells provided partial protection against chronic
infection but largely ceased to detect virus within 72 hours of challenge, demonstrating rapid
sequestration of viral replication away from T cells. Our studies revealed a strategy of immune
evasion by MNV via the induction of a CD8+ T cell program normally reserved for latent
pathogens and persistence in an immune-privileged enteric niche.

IN BRIEF
Chronic infections often cause T cell dysfunction, but how noroviruses (NV) evade immunity is
unknown. Tomov et al. show that gut-resident T cells against NV remain functional but ignorant of
chronic viral replication, suggesting that NV persists in an immune-privileged enteric niche.

Author Manuscript
Author Manuscript

Keywords
Norovirus; enteric viral persistence; T cell inflation; T cell exhaustion; tissue-resident memory T
cells

INTODUCTION

Author Manuscript

Noroviruses (NVs) are major global pathogens that cause an estimated 267 million
infections and 200,000 deaths each year (Debbink et al., 2012). Vaccine efforts have shown
promise, but complete protection against homologous challenge has not been achieved
(Atmar et al., 2011). Moreover, volunteer and epidemiologic studies have generated
conflicting data regarding the durability and protective capacity of NV immunity, while
recent reports of persistent NV shedding by immunocompetent individuals have challenged
the traditional view of NVs as acute and self-limited pathogens (Karst et al., 2014). These
data suggest the existence of viral mechanisms of immune evasion, however the
immunological determinants of NV clearance versus persistence remain poorly understood.
Most studies have used antibodies as markers of pre-existing NV immunity and have shown
Immunity. Author manuscript; available in PMC 2018 October 17.
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that, depending on the setting, such responses are neither necessary nor sufficient for
protection (Atmar et al., 2011). In contrast, cellular immunity, particularly at mucosal sites,
remains largely unexplored.

Author Manuscript

We and others have used the mouse model of NV infection (MNV) to study MNV clearance
versus persistence (Tomov et al., 2013). Early studies showed that all aspects of adaptive
immunity are required for clearance of the non-persisting strain MNV-CW3 (Karst et al.,
2014). On the other hand, a related strain, MNV-CR6, causes chronic infection even in
immunocompetent mice. Recent studies have shown that MNV-CR6 persistence depends on
the enteric microbiota and can be prevented by pre-treating mice with antibiotics (Baldridge
et al., 2015; Jones et al., 2014). Whether these findings reflect direct bacterial-viral
interactions (Kuss et al., 2011) or commensal modulation of the host antiviral immune
response (Abt et al., 2012) remains to be defined. In addition, persistent MNV-CR6 infection
can be cleared by exogenous interferon-lambda (Nice et al., 2015), however this
phenomenon is mediated by innate immunity and does not afford protection against
subsequent re-challenge with the same strain. Thus, adaptive immune responses will be
necessary to achieve durable immunity against MNV.

Author Manuscript

A key challenge to understanding MNV persistence is our limited knowledge of the hostpathogen interactions responsible for immune failure during chronic infection. Myeloid
cells, B cells, and epithelial cells can support mouse and/or human NV replication in cell
culture (Ettayebi et al., 2016; Jones et al., 2014), but the relevance of these cell types to
persistence in vivo is unclear, and the precise cellular identity and anatomical location of the
viral reservoir remain unknown. The identification of CD300lf as an MNV cellular receptor
is a major step towards addressing this issue (Orchard et al., 2016). However, it is unclear
whether CD300lf is sufficient to explain viral replication during established chronic
infection as CD300lf expression is largely restricted to dendritic cells (DCs) (Gasiorowski et
al., 2013) but persisting MNV-CR6 replicates in nonhematopoietic cells in vivo (Nice et al.,
2015).

Author Manuscript

In previous studies, we demonstrated that the non-persisting strain MNV-CW3 induces
robust virus-specific CD8+ T cell responses in the intestine (Tomov et al., 2013). In contrast,
infection with the persisting strain MNV-CR6 is associated with substantially fewer and
less-functional virus-specific CD8+ T cells, suggesting that suboptimal T cell responses may
contribute to viral persistence (Tomov et al., 2013). However, as the sequence of the
immunodominant P1519 epitope differs between these two MNV strains, it was unclear
whether the weak CD8+ T cell response to MNV-CR6 was due to intrinsic CD8+ T cell
dysfunction or suboptimal epitope binding. In the current study, we have addressed this issue
by engineering acute and chronic MNV strains that share the same immunodominant CD8+
T cell epitope. Using these strains, we demonstrate that improving the magnitude of the
primary CD8+ T cell response did not prevent viral persistence. Moreover, virus-specific
CD8+ T cells from chronic MNV infection developed a distinct transcriptional and
phenotypic signature compared to memory CD8+ T cells generated during acutely-resolved
infection. These cells showed strong similarity to inflationary effector CD8+ T cells
responding to mouse cytomegalovirus (MCMV) infection. Consistent with these
transcriptional features, virus-specific CD8+ T cells from chronic MNV infection remained
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responsive to antigen upon re-exposure, indicating that they retained functionality. MNVspecific memory CD8+ T cells mediated initial protection from challenge with a persisting
MNV strain but in most cases this protection was short-lived. Analysis of early events
following challenge of immunized mice revealed a marked deficiency in the ability of MNVspecific CD8+ T cells to respond to the chronic strain of MNV. Rather, during chronic
infection, MNV-specific CD8+ T cells were largely ignorant of ongoing viral replication in
vivo. Moreover, MNV-specific CD8+ T cells also failed to respond in vitro when co-cultured
with intestinal cells from chronically infected mice unless the intestinal cells were first lysed
to release antigen. Collectively our findings show that MNV persistence was associated with
a unique differentiation state of virus-specific CD8+ T cells. While such cells could, in some
settings, confer protection against MNV, T cell ignorance emerged early during chronic
infection, likely due to the establishment of an immunoprivileged enteric niche that
supported long-term viral replication. These findings further provide an explanation for the
emergence of chronic NV infections and may help explain heterogeneous responses in
humans.

Author Manuscript

RESULTS
Single amino acid determines the magnitude and function of MNV-specific CD8+ T cells

Author Manuscript

We previously mapped a conserved immunodominant epitope (P1519) that accounts for
~80% of the total CD8+ T cell response against MNV (Figure S1A, and (Tomov et al.,
2013)). However, P1519 differs at position 7 between strains CW3 (Tyr) and CR6 (Phe),
preventing direct comparison of epitope-specific CD8+ T cell responses. To address this
issue, we changed position 7 in P1519 from Tyr to Phe (Y→F) or Phe to Tyr (F→Y) in
MNV-CW3 and MNV-CR6, respectively, generating recombinant strains CR6F→Y and
CW3Y→F (Figure 1A). These reverse engineered viruses grew with normal kinetics in the
mouse macrophage-like RAW-264.7 cell line indicating that the changes in P1519 did not
affect viral fitness in vitro (Figure 1B).

Author Manuscript

At day 8 p.i., mice infected with MNV-CW3Y→F had significantly fewer P1519 Tetramerpositive (Tet+) CD8+ T cells in the intestine compared to MNV-CW3WT-infected mice
(Figure 1C). Conversely, infection with MNV-CR6F→Y resulted in a substantial boost in
virus-specific CD8+ T cell responses with numbers of Tet+CD8+ T cells in the intestine
approaching those from MNV-CW3WT infection (Figure 1C–D). Similar changes were
observed in the spleen where P1519-specific CD8+ T cells accounted for ~50–75% of the
MNV-induced CD44hiCD62Llo CD8+ T cells for MNV-CW3WT and MNV-CR6F→Y,
compared to 20–30% for MNV-CR6WT and MNV-CW3Y→F (Figure 1E). Moreover, the
difference in the Tet+CD8+ T cell response between MNV-CR6WT and MNV-CR6F→Y
persisted long-term (Figure 1F). Tet+CD8+ T cells responding to MNV-CR6F→Y produced
more cytokine and were more polyfunctional (i.e. co-produced cytokines more efficiently)
compared to Tet+CD8+ T cells from MNV-CR6WT-infected mice (Figures 1G, H; Figure
S1B). Conversely, MNV-CW3Y→F induced Tet+CD8+ T cells with less polyfunctionality
compared to MNV-CW3WT (Figure S1B). Moreover, the changes in P1519 did not
inadvertently create a CD4+ T cell epitope (Figure S1C) or affect the overall antibody
response (Figure S1D). Thus, position 7 of P1519 determines both the magnitude and quality
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of the CD8+ T cell response without affecting other aspects of adaptive immunity against
MNV.
MNV persistence versus clearance is independent of the CD8+ T cell response

Author Manuscript

To determine the effect of P1519-specific CD8+ T cells on MNV persistence, viral RNA was
measured in the stool and intestine following infection with the parental and epitope-swap
strains. MNV-CW3WT and MNV-CW3Y→F were efficiently cleared by ~day 10 p.i. (Figure
1I, J). By contrast, MNV-CR6F→Y established chronic infection indistinguishably from the
parental CR6WT strain (Figure 1I, J). Moreover, Tet+CD8+ T cells responding to persisting
MNV-CR6F→Y maintained high expression of granzyme B and retained their cytotoxic
potential at day 30 p.i. (Figure 1K, L), suggesting that exhaustion did not contribute to MNV
persistence. Changes in P1519 did not impact CD4+ or regulatory T cell (Treg cell) responses
(Figure S2A–C). Thus, MNV-CW3WT and CR6F→Y elicit similar adaptive immune
responses and can be used to directly compare CD8+ T cells against the same epitope in
acute versus chronic infection. Moreover, epitope reversion did not explain MNV-CR6F→Y
persistence as the F→Y mutation was maintained even after 6 months of chronic infection
(Figure 1M). Together these observations indicated that an augmented primary CD8+ T cell
response did not exert immune pressure on MNV-CR6F→Y and was not sufficient to prevent
persistence.
Distinct transcriptional profiles of Tet+CD8+ T cells in acute versus chronic MNV infection

Author Manuscript

We compared the transcriptional profiles of intestinal Tet+CD8+ T cells from mice infected
with MNV-CW3WT or MNV-CR6F→Y where the same epitope was being targeted. At day
30 p.i., 423 genes were differentially expressed by at least 2-fold (ANOVA p value <0.05).
Among genes upregulated during MNV-CR6F→Y infection were some with known roles in
CD8+ T cell differentiation such as Itga2, Il12rb2, Cxcl10, and Fas, and others encoding the
inhibitory molecules 2B4, Tim-3 and KLRG1 (Figure 2A). Genes that were downregulated
during MNV-CR6F→Y infection included Il2, Sipr1, Tcf7, Lef1, Btla, Cxcr4, Slamf6,
Ly6c2, Cd40lg, Klrk1, and Pdcd1 (Figure 2A).

Author Manuscript

Gene set enrichment analysis (GSEA) using gene ontology (GO) terms indicated that Tet
T cells from chronically-infected mice were mitotically and metabolically active and
upregulated genes involved in cell division, aerobic respiration, and lipid metabolism (Figure
2B). On the other hand, Tet+ memory CD8+ cells from resolved MNV-CW3WT infection
upregulated genes associated with adaptive immune responses, T cell receptor (TCR)
signaling, and cytokine production (Figure 2C). Thus, despite responding to the same
epitope, CD8+ T cells induced during MNV-CW3WT versus MNV-CR6F→Y infection
developed distinct metabolic and proliferative transcriptional programs.
+CD8+

Consistent with previous analyses (Tomov et al., 2013), expression of Pdcd1 encoding the
inhibitory receptor PD-1, was lower in Tet+CD8+ T cells from chronic compared to resolved
MNV infection. Another gene associated with T cell exhaustion, Btla, showed a similar
pattern of relative expression (Figure 2A). On the other hand, genes for the inhibitory
receptors 2B4 (Cd244) and Tim3 (Havcr2) were upregulated in Tet+CD8+ T cells from
MNV-CR6F→Y infection, as was KLRG-1 (Figure 2A). Moreover, protein expression
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correlated with transcriptional differences for a number of differentially transcribed genes
(Figure 2D). In sum, these data indicate an unusual differentiation state of MNV-specific
CD8+ T cells compared to typical exhausted CD8+ T cells defined in studies of chronic
LCMV and HIV infection (Wherry and Kurachi, 2015).
Distinct tissue resident CD8+ T cell subsets exist in acute versus chronic MNV infection

Author Manuscript

We have previously noted differences in the expression of several integrins on Tet+CD8+ T
cells from acute versus chronic MNV infection (Tomov et al., 2013). Gene expression
analysis confirmed 1.97-fold higher expression of Itgae (encoding CD103) in Tet+CD8+ T
cells from MNV-CR6F→Y infection (ANOVA P value <0.05). As CD103 is a marker of
tissue residence (Carbone et al., 2013), we conducted additional analyses for expression of
tissue residence memory (Trm) cell genes and proteins. At day 30 post MNV-CW3WT
infection, a significant fraction of Tet+CD8+ T cells from the lamina propria (LP) and
intraepithelial (IEL) compartments remained CD103lo (Figure 3A). By contrast, most Tet
+CD8+ T cells from the small intestine and colon of mice infected with MNV-CR6F→Y were
CD103hi (Figure 3A–B) consistent with previous observations for MNV-CR6WT (Tomov et
al., 2013). The ratio of CD103hi to CD103lo Tet+ CD8+ T cells remained constant during
MNV-CW3WT infection, but shifted to a predominantly CD103hi phenotype with MNVCR6F→Y (Figure 3C). In contrast to CD103, CD11a and CD49d were more highly
expressed on Tet+CD8+ T cells from MNV-CW3WT compared to MNV-CR6F→Y infection
(Figure 3D), consistent with differences between the WT strains (Tomov et al., 2013).
Therefore, the distinct pattern of α-integrin expression by Tet+CD8+ T cells responding to
MNV-CR6F→Y is attributable to chronic infection rather than the F→Y change in P1519.

Author Manuscript

Upregulation of CD103 is not an absolute requirement for tissue residence and CD103lo Trm
cells are critical for control of some enteric pathogens (Bergsbaken and Bevan, 2015).
Alternatively, the CD103lo Tet+CD8+ T cells from MNV-CW3WT-infected mice might be
recirculating T cells rather than true Trm cells (Carbone et al., 2013). To distinguish between
these possibilities, we used intravascular staining for CD8α (Beura et al., 2015), which
distinguished between anatomic compartments with different access to the circulation
(Figure 3E, CD8α+ vs. CD8α− cells). In the intestine, 99% of CD8+ LPL and IEL were
inaccessible to the i.v. administered antibody indicating that they were not from blood
contamination (Figure 3E, green gates). Furthermore, these gut-associated lymphocytes
contained both CD103lo and CD103hi Tet+ cells, suggesting that both CD103-defined
subsets were Trm cells (Figure 3F).

Author Manuscript

To further investigate MNV-specific CD8+ T cell tissue residence, we applied GSEA using a
Trm cell signature (Mackay et al., 2013). As expected, Trm cell genes were enriched in
intestinal relative to splenic Tet+CD8+ T cells at all time points for both viruses (Figure S3).
Comparison of enteric Tet+CD8+ T cells from MNV-CW3WT versus MNV-CR6F→Y showed
a more prominent Trm cell program induced early during acutely-cleared infection (Figure
3G). By day 15, this enrichment bias was no longer evident (Figure 3H), while by day 30
p.i., the Trm cell signature was more highly enriched in Tet+CD8+ T cells from MNVCR6F→Y infection (Figure 3I). Although at day 8 p.i. Trm cell signature enrichment was
driven by 12 core genes, only 5 genes contributed at day 30 p.i. (Figure 3J). Therefore Tet
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T cells from either infection upregulated Trm cell-associated genes but in the case of
MNV-CR6F→Y induction of the Trm cell program appeared to be delayed.

Author Manuscript

Next, we used a MNV-CW3WT and MNV-CR6F→Y coinfection model. We reasoned that if
the timing of Trm cell differentiation was important for the outcome of infection, either
MNV-CW3WT would induce early Trm cells leading to control of the co-infecting MNVCR6F→Y or co-infection with MNV-CR6F→Y would suppress Trm cell differentiation.
Coinfected mice developed chronic infection with indistinguishable kinetics from mice
infected with MNV-CR6F→Y alone indicating that MNV-CW3WT failed to induce a
protective CD8+ T cell response (Figure 3K, L). Moreover, at day 30 both persistently
infected mice from the MNV-CR6F→Y alone and the co-infected group had higher
expression of CD103 on Tet+CD8+ cells compared to resolved MNV-CW3WT infection
(Figure 3M). Thus, although CD8+ T cells are necessary for clearance of MNV-CW3WT
(Chachu et al., 2008), these cells failed to prevent viral persistence in the setting of
coinfection. Moreover, the persisting MNV strain determined the long-term phenotype of
Tet+CD8+ T cells. Thus, a distinct viral mechanism of immune evasion, rather than intrinsic
CD8+ T cell dysfunction enables MNV-CR6F→Y persistence.
Persistent MNV infection induces a unique transcriptional program in Tet+CD8+ T cells

Author Manuscript
Author Manuscript

Next, we defined transcriptional signatures of CD8+ T cells responding to persisting or
resolved MNV infection using differentially expressed genes at day 30 p.i. (Figure 2A). We
tested for enrichment of these MNV signatures in the transcriptional profiles of CD8+ T
cells from acute versus chronic lymphocytic choriomeningitis virus (LCMV) infection
(Doering et al., 2012). Indeed, GSEA revealed enrichment for the MNV-CR6F→Y signature
in CD8+ T cells from chronic LCMV infection (Figure S4A). Conversely, the MNV-CW3WT
signature was enriched in functional memory CD8+ T cells from resolved LCMV infection
(Figure S4B). The transcriptional similarity between CD8+ T cells responding to chronic
MNV and LCMV infections was driven, in part, by genes encoding exhaustion markers
Tim3 and 2B4, integrin CD49b, and cytokine CXCL10 (Figure S4A). However, genes for
other key markers of exhaustion, such as Pdcd1, were not part of the MNV-CR6F→Y CD8+
T cell signature and did not contribute to core enrichment in Figure S4A. To investigate this
question further, we used published immunologic signatures to perform comprehensive
GSEA of Tet+CD8+ T from day 30 MNV-CR6F→Y infection. There was significant
enrichment of several exhaustion signatures derived from the LCMV model (Figure 4A)
consistent with Figure S4A (Doering et al., 2012; West et al., 2011). However, the
transcriptional profile of Tet+CD8+ T was also enriched for effector signatures (Figure 4B),
defined as genes upregulated on day 8 versus 30 of LCMV or vaccinia virus infection. As
effector and exhausted CD8+ T cells share features of activation (Doering et al., 2012;
Singer et al., 2016), we used leading edge analysis to determine whether the same core
genes contributed to enrichment for both types of signatures during MNV-CR6F→Y
infection. Of the 489 genes driving enrichment for the exhaustion and effector signatures in
Figure 4A–B, only 38 contributed to enrichment of both an exhaustion and an effector
(Figure 4C). Moreover, only Litaf, encoding lipopolysaccharide (LPS)-induced tumor
necrosis factor (TNF), contributed to more than one of the exhaustion and effector signatures
used in the comparison. Thus, Tet+CD8+ T cells from chronic MNV-CR6F→Y infection had
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features of both exhausted and effector CD8+ T cells and these characteristics were largely
driven by non-overlapping sets of genes, possibly reflecting recent activation and/or
heterogeneity in the populations analyzed. By contrast, the transcriptome of Tet+CD8+ T
cells from resolved MNV-CW3WT infection enriched for signatures of memory and/or
quiescence, consistent with viral clearance (Figure S4C).

Author Manuscript

Given the preserved effector features of Tet+CD8+ T cells from chronic MNV infection, we
considered the murine cytomegalovirus (MCMV) model of viral persistence that is
characterized latency and reactivation. These viral dynamics give rise to inflationary virusspecific CD8+ T cells that maintain an effector phenotype and do not become exhausted
despite repeated antigenic stimulation (Snyder, 2011). GSEA showed enrichment of an
inflationary effector CD8+ T cell signature (Quinn et al., 2015) in the transcriptional profile
of CD8+ T cells responding to persistent MNV-CR6F→Y infection (Figures 4D and S4D),
suggesting long-term maintenance of a functional effector CD8+ T cell (Teff cell) response.
Indeed, the normalized enrichment scores (NES) for effector signatures in Figure 4B and 4D
were higher than the NES for exhaustion signatures in Figure 4A (Figure 4E). Moreover, of
the 45 genes that contributed to core enrichment of the MCMV Teff cell signature (Figure
S4D), 18 (40%) also contributed to enrichment of other effector signatures (Figure 4F) while
none contributed to enrichment of exhaustion signatures. Therefore, the transcriptional
similarities between CD8+ T cells responding to chronic MNV and latent MCMV infection
can be largely attributed to effector genes.

Author Manuscript

Phenotypic features of inflationary CD8+ T cells include upregulation of granzyme and
CX3CR1 and downregulation of the co-stimulatory molecules CD27, CD28, and GITR
(Snyder, 2011; van de Berg et al., 2012; Welten et al., 2013). Indeed, at day 30 of MNVCR6F→Y compared to MNV-CW3WT infection Tet+CD8+ T cells had higher expression of
granzyme B and lower expression of CD28 and GITR proteins (Figure S4E). Consistent
with their inflationary differentiation pattern, Tet+CD8+ T cells during chronic MNVCR6F→Y infection persisted long-term and comprised a significant fraction of intestinal
CD8+ T cells at day 60 p.i. (Figure 4G). Thus, Tet+CD8+ T cells from chronic MNVCR6F→Y infection share transcriptional and phenotypic features with inflationary Teff CD8+
T cells from latent MCMV infection.
Tet+CD8+ T cells from chronic MNV infection respond to antigen in vivo

Author Manuscript

To define in vivo functionality, Tet+CD8+ T cells from chronic MNV-CR6F→Y infection
were isolated, labeled with cell trace violet (CTV), and adoptively transferred into congenic
recipients. These recipients were either naïve, acutely infected with MNV-CW3WT (day 4
p.i.) or chronically infected with MNV-CR6F→Y (day 60 p.i.) (Figure 5A–C). As expected, 5
days post transfer, donor Tet+CD8+ T cells had not divided in naïve hosts (Figure 5A).
However, in mice acutely infected with MNV-CW3WT, donor Tet+CD8+ T cells divided
extensively, expanded in number, and homed to the spleen, mesenteric lymph nodes
(MLNs), and intestine (Figure 5B). Donor Tet+CD8+ T cells were particularly abundant in
the intestine where they accounted for up to 80% of all donor-derived CD8+ T cells (Figure
5D). Thus, MNV-specific CD8+ T cells isolated even after 60 days of chronic infection were
still capable of mounting robust responses to viral antigen in vivo during acute infection.
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However, when the same Tet+CD8+ T cells were adoptively transferred to recipients that
were chronically infected with MNV-CR6F→Y, these cells did not expand in number and
were difficult to detect 5 days post transfer (Figure 5C). In a few chronically infected
recipients, donor Tet+CD8+ T cells could be found in the intestine but these cells had not
divided and accounted for less than 10% of all donor CD8+ T cells (Figure 5D), suggesting
they had not encountered antigen. Consistent with this conclusion, viral loads in these mice
remained unchanged after the adoptive transfer (data not shown).

Author Manuscript
Author Manuscript

The failure of adoptively transferred Tet+CD8+ T cells to respond to MNV-CR6F→Y
suggested that these cells were ignorant of persisting antigen. Alternatively, poor donor
responses might be due to competition from pre-existing host CD8+ T cells (Quinn et al.,
2015). Therefore, we repeated the adoptive transfer experiment in Figure 5A–C using
Thy1.1 (recipients) and Thy1.2 (donors) as congenic markers, and used an anti-Thy1.1
antibody to selectively deplete host T cells from recipients prior to the adoptive transfer
(Figure S5A–B). Five days post transfer, donor Thy1.2+CD8+ T cells were detected in all
tissues examined but had not proliferated significantly in most mice (Figure S5C). Depletion
of host T cells did enhance overall donor cell survival, especially in MLN, however this
effect was modest and observed in both naïve and chronically-infected mice, suggesting
homeostatic proliferation rather than an antigen-specific response (Figure S5C). Indeed,
most CTV-low donor CD8+ T cells were not Tet+ in either naïve or CR6F→Y-infected mice
(Figure 5E–G). Adoptively-transferred CD8+ T cells were most abundant in the MLN of 2
out of 5 persistently infected Thy1.1-depleted recipients (Figure S5C, blue circles in MLN
plot), however even in these mice Tet+ cells accounted for less than 0.5% of total donor cells
(Figure 5H). Similarly, Tet+ cells accounted for at most 11% of donor CD8 T cells in the
IEL and this was seen in just 1 out of 5 recipients (Figure 5H). Thus, even when depletion of
host T cells gave an overall survival advantage, Tet+ cells failed to respond to chronic MNVCR6F→Y infection.
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Consistent with Figure 5B, when Thy1.2+CD8+ T cells were adoptively transferred into
mice acutely infected with MNV-CW3WT, Tet+ donor cells proliferated robustly even
without host T cell depletion (Figure 5G). By day 5 post transfer, virtually all Tet+ donor
cells had diluted CTV and accounted for nearly half of donor cells in the gut (Figure 5H).
Compared to Figure 5B, donor Tet+ cell expansion was less robust (red bars in Figure 5H
versus 5D), consistent with the different timing of these adoptive transfers (recipient mice
day 4 p.i. in Figure 5B versus day 1 p.i. in Figure 5H) and the fact that MNV-CW3WT viral
titers peak at ~day 4 (data not shown). Collectively, these data demonstrate that despite
having the capacity to respond to antigen in vivo, virus-specific CD8+ T cells fail to do so
during chronic MNV-CR6F→Y infection and this defect is not due to T cell competition.
Therefore, Tet+CD8+ T cells in persistently infected mice might be limited by an inability to
efficiently detect viral antigen.
Preexisting CD8+ T cell immunity confers partial protection against chronic MNV
Given the response of Tet+CD8+ T cells to MNV-CW3WT (Figure 5C), we tested the
effectiveness of pre-existing immunity against MNV-CR6F→Y. Mice that had previously
cleared MNV-CW3WT or MNV-CW3Y→F were challenged with MNV-CR6F→Y or MNV-
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CR6WT and protection was measured by viral shedding and tissue titers. We carried out both
“matched” and “mismatched” experiments in which the prime and challenge strains had the
same or different P1519 epitopes. When taken together, there was no consistent pattern for
priming strain related to control upon challenge (data not shown). Therefore, we combined
data for MNV-CW3WT and MNV-CW3Y→F-immune mice and report all outcomes based on
the chronic strain used in the challenge.
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As expected, all non-immunized mice became chronically infected when challenged with
MNV-CR6WT or MNV-CR6F→Y (Figure 6A–B, circles). Mice immunized with MNVCW3WT or MNV-CW3Y→F and then challenged with MNV-CR6WT also developed chronic
infection (Figure 6A–B, solid squares). By contrast, all immune mice challenged with
MNV-CR6F→Y had decreased viral shedding for the first 48–96 hours p.i. (Figure 6A, open
squares; time points in blue box), although in most cases replication of the challenge MNVCR6F→Y virus eventually rebounded. However, ~1/3 of animals achieved long-term viral
control with undetectable titers in the stool for at least ~30 days despite being co-housed
with mice who remained infected and shedding virus (Figure 6A). At day 30 post challenge
these protected mice also had undetectable viral titers in the proximal colon (Figure 6B).
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These data showed that early viral control following MNV-CR6F→Y challenge was
universal, whereas long-term protection was sporadic (Figure 6C). Long-term viral control
did not correlate with the number or functionality of Tet+CD8+ T cells (data not shown),
and boosting MNV-CW3WT-immune mice with a recombinant vaccinia virus expressing the
P1519Y epitope did not improve outcomes to MNV-CR6F→Y challenge (data not shown)
despite significantly augmenting the P1519-specific CD8+ T cell response (see Figure S6A,
B). Taken together, these observations suggested that long-term protection was likely due to
events that occurred early after viral challenge and prevented establishment of a niche for
MNV-CR6F→Y persistence. Consistent with this interpretation, in 4 out of 6 primed mice
that had developed chronic MNV-CR6F→Y infection (see box in Figure 6B) the F→Y
mutation was preserved at day 30 post challenge (Figure 6D). Similarly, MNV-CR6F→Y
sequences from the fecal pellets of 4 other primed and chronically-infected mice also
contained the F→Y mutation (data not shown). These findings further suggested that CD8+
T cells failed to exert immune pressure on MNV-CR6F→Y in the chronic phase of infection.
In 2 of the primed and chronically infected mice, the P1519Y epitope had, in fact, mutated
back to P1519F (Figure 6D). Moreover, this was a true reversion since the Phe codon in these
mutant sequences was TTC, whereas it is TTT in the wild-type CR6 strain (compare to
Figure 1M). We hypothesize that this sequence change represents an alternative pathway of
viral escape early after challenge when CD8+ T cells exerted some degree of control over
viral replication.
As partial protection against chronic MNV was observed for MNV-CR6F→Y but never for
MNV-CR6WT or in unimmunized mice, we surmised that such protection was mediated by
CD8+ T cells. To directly test this conclusion, a subset of immunized mice was depleted of
CD8+ T cells (Figure S6C) and viral titers were measured at early time points post MNVCR6F→Y challenge. Consistent with our previous observations, immunized mice with intact
CD8+ T cells controlled viral replication at early time points (Figure 6E, squares). By
contrast, most mice treated with anti-CD8β had high viral titers in the proximal colon at
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days 4 and 6 post challenge (Figure 6G, triangles). Of note, we did not detect MNV in the
liver or spleen of these CD8-depleted mice, consistent with the gut-specific tropism of
MNV-CR6 (Nice et al., 2013). Thus, CD8+ T cells were necessary for early enteric control
of MNV-CR6F→Y in immunized mice.
Inconsistent detection of antigen by Tet+CD8+ T cells early after MNV-CR6F→Y challenge

Author Manuscript

Prime-challenge data indicated a narrow window for Tet+ CD8+ T cells to clear MNVCR6F→Y (Figure 6A), while the adoptive transfers suggested that these cells were ignorant
of viral replication during chronic infection (Figure 5C). To investigate these dynamics
further, we generated a recombinant vaccinia virus expressing the P1519Y epitope (rVV519Y)
and used it to boost the P1519-specific CD8+ T cell response in MNV-CW3WT-immune mice
(Figure S6A–B). We used this prime-boost strategy to generate large numbers of Tet+CD8+
T cells, labeled these cells with CTV, and adoptively transferred them to congenic recipients.
Recipients mice were either naïve or at different time points of MNV-CW3WT (day 1 or 7)
or MNV-CR6F→Y (day 1, 7, or 30) infection.
As expected, no proliferation of donor Tet+CD8+ T cells was observed in naïve recipients 5
days after adoptive transfer (Figure 7A). By contrast, donor Tet+CD8+ T cells divided
extensively in all recipients at day 1 p.i. with MNV-CW3WT (Figure 7B). These, donor Tet
+CD8+ T cells homed to the spleen and MLN, as well as to the intestinal mucosa and LP
where they accumulated to the highest frequency (Figure 7G). Consistent with the viral
clearance kinetics for MNV-CW3WT (see Figure 1) there was little division or accumulation
of donor Tet+CD8+ T cells in MNV-CW3WT-infected recipients at day 7 p.i., though
occasional CTV dilution likely reflected presence of residual antigen (Figure 7C).
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When Tet+CD8+ T cells were adoptively transferred to MNV-CR6F→Y-infected recipients at
days 1 or 7 p.i., we observed heterogeneous responses (representative plots in Figure 7D–E).
In some recipients, essentially no division of donor Tet+CD8+ T cells took place, while in
others Tet+ donor cells divided extensively, although not to the same extent as with MNVCW3WT (Figure 7B versus D–E). When donor Tet+ cells responded to MNV-CR6F→Y, they
accumulated primarily in the intestine where P1519-specific cells accounted for at most 30%
of total donor CD8+ T cells (compared to 80% for MNV-CW3WT) (Figure 7G). At day 5
post transfer, all MNV-CR6F→Y infected mice had detectable virus in the colon and there
was no correlation between the extent of donor Tet+CD8+ T cell proliferation and intestinal
viral titers in individual mice (data not shown). This was expected since the number of
MNV-specific CD8+ T cells following adoptive transfer was low compared to intact MNV
immune mice and these mice lacked preexisting CD4+ T cell and B cell immunity.
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Despite ongoing viral replication (and consistent with Figure 5C), no significant division of
donor CD8+Tet+ cells took place in recipients at day 30 post MNV-CR6F→Y infection and
few donor cells were detected at this late time point (Figure 7F, G). Collectively, these data
suggested that although MNV-specific CD8+ T cells could sense and respond to MNVCR6F→Y early after infection, these responses were sporadic and less robust than for MNVCW3WT. Moreover, the ability of Tet+CD8+ T cells to detect ongoing MNV-CR6F→Y
replication waned over time and was nearly absent in established chronic infection.
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The preserved functionality and progressive inability of Tet+CD8+ T cells to detect ongoing
viral replication suggested that MNV-CR6F→Y was inaccessible to CD8+ T cells during
established chronic infection. Alternatively, MNV-CR6F→Y might directly antagonize
immune cell function via virally-encoded proteins (Zhu et al., 2016; Zhu et al., 2013). To
distinguish between these possibilities, we designed an in vitro experiment to “force”
interactions between Tet+CD8+ T cells and cells infected with MNV-CR6F→Y. CD8+ T cells
from the spleens of day 30 MNV-CR6F→Y-infected mice were labeled with CTV and
incubated with single-cell intestinal suspensions from congenic mice that were either naïve
or also persistently infected with MNV-CR6F→Y. These “intestinal preps” contained
multiple cell types including epithelial cells, fibroblasts, and immune subsets from the
intraepithelial and LP compartments (data not shown). Although the cellular reservoir of
persisting MNV-CR6F→Y is currently unknown, we reasoned that cells harboring virus were
likely to be present in intestinal preps.
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Intestinal preps from naïve mice did not stimulate Tet+CD8+ T cell division (Figure 7H).
Preps from persistently-infected mice also failed to induce an MNV-specific CD8+ T cell
response (Figure 7I), consistent with in vivo observations (Figure 5C). To determine whether
host or viral factors prevented Tet+CD8+ T cell responses, intestinal preps from chronically
infected mice were lysed via freeze-thaw to release potentially inaccessible intracellular
viral antigens and mixed with splenocytes from naïve mice to act as antigen presenting cells
(APC). In this case, Tet+CD8+ T cells responded by dilution of CTV consistent with antigen
release from a cellular viral reservoir and presentation by splenic APC (Figure 7J). Similar
results were obtained when bone marrow-derived DCs were used as APC (Figure S7).
Moreover, proliferation of Tet+ CD8+ T cells in these in vitro assays was antigen-specific, as
it was not observed with lysed intestinal preps from naïve mice (Figure S7A). These data
suggested restricted availability and/or release of viral antigen from the intestinal cellular
reservoir despite continued replication of MNV-CR6F→Y in vivo. Taken together, our in
vivo and in vitro experiments support a mechanism of CD8+ T cell evasion by MNV based
on persistence in an immune-privileged enteric niche.

DISCUSSION
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Two challenging aspects of NV biology have recently been appreciated. First, NVs cause
chronic infections in some immunocompetent individuals thereby creating a potential
reservoir for viral evolution and spread (Karst et al., 2014). Second, NVs evade adaptive
immune responses even in previously vaccinated individuals who have robust NV-specific
antibody titers (Atmar et al., 2011). Understanding why adaptive immunity fails to prevent
or clear NV infections can facilitate future vaccine and public health efforts.
CD8+ T cells are critical for control of many mucosal pathogens including NVs (Chachu et
al., 2008). However, the impact of chronic enteric infection on Trm cell responses and
differentiation remains poorly understood. As chronic viral infections are often facilitated by
T cell dysfunction, defining the features of T cell failure could have implications for
therapeutic interventions and preventative vaccines. Using the MNV model we discovered
two key features of the CD8+ T cell response and protective immunity during chronic
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infection. First, MNV-specific CD8+ T cells retained functional responsiveness and did not
display typical features of exhaustion. Indeed, MNV-specific CD8+ T cells maintained
transcriptional features of activation resembling inflationary effector CD8+ T cells from
herpesvirus infections. Second, there was a narrow window of opportunity for CD8+ T cells
to exert protection against chronic MNV infection, leading to an apparent paradox of
continued robust viral replication despite a largely functional antiviral CD8+ T cell response.
Our findings point to a mechanism of largely immunologically undetectable persistence of
an RNA virus in the intestinal tract.
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While pathogen persistence is not unique to MNV, our data suggest an unusual pattern of
immune evasion. First, the immunodominant P1519Y epitope did not revert to the less
immunogenic 519F variant following primary and most secondary infections, suggesting
that antigenic escape is not a major pathway facilitating MNV persistence. Second, CD8+ T
cell exhaustion or senescence did not develop in P1519Y-specific CD8+ T cells, as these cells
remained functional even after 30 days of chronic infection. Third, overt tolerance to MNVCR6F→Y also appears unlikely given the absence of Treg cell expansion and the robust
response of P1519Y-specific CD8+ T cells when adoptively transferred to MNV-CW3WTinfected mice.
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A fourth possibility is that Tet+CD8+ T cells fail to clear MNV-CR6F→Y due to limited
access to viral antigen during chronic infection. True CD8+ T cell ignorance is thought to
arise from insufficient anatomical access to antigen and/or lack of costimulatory signals
(Woodham et al., 2016). However, in the case of established chronic MNV-CR6F→Y
infection, the effector properties of P1519-specific CD8+ T cells and their transcriptional
similarity to inflationary MCMV-specific responses suggest that these cells do, at least
occasionally, encounter and respond to antigen in vivo, but such interactions may be
transient and/or inefficient.
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How does a virus persistently replicating at high levels induce a CD8+ T cell transcriptional
program normally reserved for latent pathogens? MNV cellular tropism may be at the core
of this question and while the identity of the in vivo cellular reservoir remains poorly
understood, our data may be relevant for elucidating the pathogenesis of this chronic enteric
infection. Although we demonstrate a role of CD8+ T cells in preventing chronic MNV
infection, at least in some mice, our data also show that these cells have a narrow window of
opportunity to prevent persistence. This observation suggests a possible “switch” in tropism
associated with the transition to viral persistence. CD300lf+ DCs can support MNV-CR6
infection in vitro and may be necessary for at least the initial establishment of infection in
vivo (Orchard et al., 2016). Thus, one possibility is that initial DC infection allows priming
and early control of MNV-CR6F→Y infection by CD8+ T cells, but subsequently viral
persistence is established in a cell type that is relatively inaccessible or unrecognizable by
Tet+CD8+ T cells. The transcriptional program of MNV-specific CD8+ T cells from chronic
infection does, however, implicate occasional re-stimulation with antigen in vivo perhaps
due to low-level release from the viral reservoir. Moreover, the CD103 status of MNVspecific CD8+ T cells in acutely resolved versus chronic infection may be relevant. For
example, data from the Yersinia model show that the physical proximity of CD103lo Trm
cells to antigen-presenting cells is critical for successful pathogen clearance (Bergsbaken
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and Bevan, 2015). Whether the distinct patterns of CD103 expression on Tet+CD8+ T cells
from resolved versus chronic MNV infection reflect differences in viral tropism and local
immune environment, and whether modulating this axis could have antiviral effects will be
interesting to interrogate in the future.
We have shown that a robust and functional CD8+ T cell response fails to prevent MNV
persistence. The behavior of MNV-specific CD8+ T cells during chronic infection suggests a
“blind spot” in their ability to perceive antigen. Whether such ignorance is the result of a
maladaptive CD8+ T cell differentiation pattern or viral replication inside an
immunoprivileged enteric niche remains to be determined and will have important
implications for the design of future NV vaccines.

STAR METHODS
Author Manuscript

Contact for Reagent and Resource Sharing
Further information and requests for reagents may be directed to Vesselin Tomov
(tomovv@pennmedicine.upenn.edu)
Experimental Model and Subject Details
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Mice—Wild type C57Bl/6J female mice age 6–8 weeks were obtained from Jackson
Laboratory, Bar Harbor, ME. MNV-free status of mice from Jackson Laboratory was
confirmed by serology testing and qPCR. After arrival, mice were maintained MNV-free in
designated cages with bedding and food changes done separately from other mice by the
investigators. Periodic monitoring of naïve controls was carried out to confirm MNV-free
status. Mice were infected by oral gavage with 1×106 PFU of MNV delivered in 200 μl
culture medium (RPMI with 10% fetal bovine serum). For vaccinia virus boost experiments,
mice were injected intraperitoneally with 1×106 PFU of rVV519Y in 200 μl culture medium.
All mice were used in accordance with Institutional Animal Care and Use Committee
guidelines for the University of Pennsylvania.
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Mouse noroviruses—MNV strains CW3Y→F and CR6F→Y were generated from the
parental strains MNV-1.CW3 (GenBank accession # EF014462) and MNV-1.CR6 (GenBank
accession # EU004676). Overlap extension PCR was used to generate fragments containing
the Y→F or F→Y mutations as previously described (Higuchi et al., 1988). For MNVCW3Y→F, primers (5′-CCCCTTGCCCCCCCAATTGGTCCC-3′) and (5′GGCCAATTGAAAAAGGCGAGGAACCCAACTGACGACC-3′) were used to generate
the first fragment, and primers (5′CCTCGCCTTTTTCAATTGGCCTCTGTGGGAAGTTTGGC-3′) and (5′GGAGTGAATTCTAGCGGCCGCTAGAATTCCG-3′) were used to generate the second
fragment. The product from the overlap extension step was cloned into the MNV-CW3
backbone between endonuclease restriction sites ApaL1 and Not1. For MNV-CR6F→Y,
primers (5′-CCCCTTGCCCCACCCCTAGGCCCC-3′) and (5′CGGAGGCCAATTGGTAGAGGCGGGGGACCCAGCTGACAACC-3′) were used to
generate the first fragment, and primers (5′GCCTCTACCAATTGGCCTCCGTGGGAAGCTTGG-3′) and (5′-
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GGAGTGAATTCTAGCGGCCGCTAGAATTCCG-3′) were used to generate the second
fragment. The product from the overlap extension step was cloned into the MNV-CR6
backbone between endonuclease restriction sites Pvu1 and Not1. All constructs were
sequenced to confirm successful insertion of the mutant sequences. Viral stocks of the wild
type and mutant viruses were generated by transfecting virion-encoding plasmids into 293T
cells and transferring supernatant onto RAW 264.7 cells as previously described (Tomov et
al., 2013). Briefly, 293T cells were transfected using FuGENE-HD reagent (Promega,
Madison, WI) according to the manufacturer’s protocol (FuGENE:DNA ratio of 5:2). After
48 hours, transfected 293T cells were lysed by freeze-thaw, cellular debris was removed by
centrifugation (10 minutes, 3,000 g, 4°C), and the supernatant was transferred onto RAW
264.7 cells that had been plated at 2×106 cells/well in 6-well plates 24 hours earlier. After 48
hours, RAW 264.7 cells were freeze-thawed and supernatant was purified from cellular
debris as above. Viral stock titers were determined by plaque assay on RAW264.7 cells.
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Recombinant vaccinia virus—Recombinant vaccinia virus rVV519Y was generated by
cloning an insert containing the P1519Y sequence between restriction sites EcoR1 and Nhe1
in vector pRB21 (Blasco and Moss, 1995). Top (5′AATTCATGAGTTGGGTTCCTCGCCTTTACCAATTGTAG-3′) and bottom (5′CTAGCTACAATTGGTAAAGGCGAGGAACCCAACTCATG-3′) oligonucleotides were
annealed and 5′ phosphate groups were added using T4 polynucleotide kinase prior to
cloning into the pRB21 vector. Successful insertion was confirmed by DNA sequencing.
Recombinant vaccinia virus was produced by homologous recombination in CV-1 cells and
triple plaque purification on 143B cells in the presence of 5mg/ml 5′-bromo-2′deoxyuridine as previously described and additional stocks were prepared in BSC40 cells
(Wherry et al., 2001).
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Lymphocyte isolation and flow cytometry—Lymphocyte isolation from spleens,
mesenteric lymph nodes, intestinal epithelium, and intestinal lamina propria was performed
as previously described (Tomov et al., 2013). Briefly, spleens, and mesenteric lymph nodes
were harvested in 2 ml cold (4°C), sterile culture media (RPMI with 10% fetal bovine
serum), and homogenized through 70 μm cell strainers. In the case of spleens, red blood
cells were lysed with ammonium-chloride-potassium (ACK) lysing buffer (Life
Technologies, Grand Island, NY) for 2 minutes, and washed in cell culture media. Small
intestines were dissected free of fat and Peyer’s patches, cut open longitudinally, washed
clean of fecal material in PBS, and placed in 10 ml cold culture media. To remove epithelial
cells, intestines were incubated in stripping buffer (PBS containing 5 mM EDTA, 1 mM
dithiothreitol, 5% fetal bovine serum, 100 IU/ml penicillin, and 100 μg/ml streptomycin) and
shaken at 160 rpm for 10 minutes at 37°C. After discarding the supernatant, intestines were
incubated again in stripping buffer and shaken at 160 rpm for 20 minutes at 37°C. The
supernatant containing intestinal epithelial cells (IEL) was passed through a 70 μm cell
strainer, washed in culture media, re-suspended in culture media containing 40% Percol, and
subjected to centrifugation at 600g, room temperature, for 20 minutes (without break).
Following centrifugation, the supernatant was carefully removed and cell pellets were
washed in culture media. After IEL stripping, lamina propria lymphocytes (LPL) were
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isolated by incubating intestines in cell media containing 0.5 mg/ml collagenase/dispase
(Genetech, South San Francisco, CA) and 20 μg/ml DNaseI (Sigma-Aldrich, St. Louis, MO)
for 20 minutes at 37°C and shaking at 160 rpm. LPL were passed through a 70 μm cell
strainer, washed, and centrifuged in 40% Percol as described above. LPL and IEL were
isolated from the small intestine except in Figure 3B where they were isolated from the
colon. In vitro stimulation with peptides P1519F and P1519Y was carried out for 5 hours at
37°C with 0.4 μg/ml of peptide in the presence of GolgiStop and GolgiPlug (BD
Biosciences, San Diego, CA) as previously described (Tomov et al., 2013). Cells were fixed
and permeabilized using a Cytofix/Cytoperm kit (BD Biosciences, San Diego, CA) or FoxP3
Fixation/Permeabilization kit (eBioscience, San Diego, CA) according to the manufacturer’s
protocol. MHC Class I-peptide tetramers used in this study have been previously described
(Tomov et al., 2013). Antibodies used are documented in the Key Resource Table. Data
analysis was performed using FlowJo (version 10.3) software (LLC, Ashland, OR). Dead
cells were removed by gating on a LIVE/DEAD Aqua kit (Invitrogen, Carlsbad, CA) versus
forward scatter (FSC-H).
Adoptive transfers—Splenocytes from donor mice were harvested and isolated as
described in the lymphocyte isolation and flow cytometry section above. Where indicated,
enrichment for CD8+ T cells was performed using a Dynal Mouse CD8+ Negative Isolation
Kit (Invitrogen, Carlsbad, CA) per manufacturer’s instructions. Cells were counted and
1×108 cells were labeled in 5 ml of 15 μM Cell Trace Violet (CTV) (Invitrogen, Carlsbad,
CA). Labeling with CTV was done at room temperature for 10 minutes in the dark. Cells
were then washed 3 times in cold PBS with 0.1% BSA, counted, and injected i.v. into
recipient mice as indicated.
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Immune cell depletion—Depletion of CD8+ T cells was performed using anti-mouse
CD8β (Lyt 3.2) antibody, clone 53-5.8 from Bio X Cell, Lebanon, NH. Mice received 2
injections of 200 μg and 2 injections of 500 μg of the antibody i.v. on days -7, -5 and then -3
and 0 relative to challenge infection. For Thy1.1 depletion, anti-mouse Thy1.1 antibody,
clone 19E12 was used. Mice received 3 injections of 200 μg IP on days -7, -4, and -2 prior to
adoptive transfer.
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In vitro cytotoxicity—The cell killing assay was carried out as previously described
(Odorizzi et al., 2015). Briefly, cells from MLN of naïve CD45.1 mice were labeled with 50
nM CTV (“dim” cells) or 1 μM CTV (“bright” cells). The CTVdim cells were incubated with
4 μg/ml of P1519Y peptide, whereas CTVbright cells were incubated with 4 μg/ml of GP33
peptide for 2 hours at 37°C. After two hours, the pulsed cells were washed and 2×103
CTVdim cells were mixed with 2×103 CTVbright cells. CD8+ T cells were isolated from the
spleen of day 30 MNV-CR6F→Y and day 30 MNV-CW3WT CD45.2 mice. These CD8+ T
cells were analyzed by flow cytometry to determine the fraction of Tet+ cells. CD8+ T cells
from MNV-CR6F→Y or MNV-CW3WT containing the same number of Tet+ cells were
added to wells with CTVdim and CTVbright target cells. After 18 hours at 37°C, target cells
were analyzed by flow cytometry and the percent-specific lysis was calculated as 100 × [1 −
(%CTVdim/%CTVbright)].
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In vitro MNV-CR6F→Y detection—Enrichment for CD8+ T cells was carried out using a
Dynal Mouse CD8+ Negative Isolation Kit (Invitrogen, Carlsbad, CA) according to
manufacturer instructions. Lysis of intestinal preps was carried out via freeze-thaw followed
by centrifugation of the sample to remove cell debris. Bone marrow-derived DCs were
isolated from the femurs of naïve mice and incubated in RPMI 1640 (Corning-Cellgro,
Corning, NY) containing 10% fetal bovine serum, 2mM L-glutamine, 50 μM 2mercaptoethanol, 100 IU/ml penicillin, 100 μg/ml streptomycin, and 20 ng/ml GM-CSF for
6 days with addition of fresh medium every 3 days.
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Cell sorting for gene expression studies—Mice were infected with MNV-CW3WT or
MNV-CR6F→Y as described above and splenocytes (SPL) and intestinal epithelial
lymphocytes (IEL) were isolated at days 8, 15, and 30 p.i. For each time point 3 or 4
independent biological replicates were used, where a “replicate” was defined as pooled IELs
or SPLs from 5 individual mice. For SPL, a Dynal Mouse CD8+ Negative Isolation Kit
(Invitrogen, Carlsbad, CA) was used to enrich for CD8+ T cells. Cells were counted and
stained for viability, CD8, tetramer (Tet), and “dump” markers CD19, CD14, and NK1.1. All
samples were maintained at 4°C. Sorting for live CD8+Tet+Dump− cells was done on a
FACS Aria II cytometer (BD Immunocytometry Systems, San Jose, CA). Each biological
replicate contained an average of 30,000 Tet+CD8+ T cells from the spleen or 10,000 Tet
+CD8+ T cells from IELs. Sample purity ranged from 92 to 99%. Sorted cells were
resuspended in 700 μl Trizol vortexed for 1 minute, and stored at −80°C pending genomic
analysis.
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RNA from sorted cells was isolated, processed, amplified, labeled, and hybridized to
MoGene 2.0 Micorarrays (Affymetrix, Santa Clara, CA) at the Molecular Profiling Facility
at the University of Pennsylvania. Affymetrix Expression Console 1.4 software was used to
process, quality control, and quantile normalize fluorescent hybridization signals with the
Robust Multichip Averaging method as described (Doering et al., 2012). Transcripts were
log2 normalized. Hierarchical Clustering was performed with Gene Pattern, and Gene Set
Enrichment Analysis was performed with GSEA software (Subramanian et al., 2005).
Viral titer measurement—Viral titer in fecal pellets and tissues was measured by qPCR
using methods and primers previously described (Tomov et al., 2013).
Quantification and Statistical Analysis
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Statistical parameters including number of biological replicates and repeat experiments, data
dispersion and precision measures (mean and SEM), and P values for statistical significance
by Student’s T test and Fisher’s exact 2-tailed test are reported in the Figures and Figure
Legends. Statistical analysis was performed using GraphPad Prism 7.
Data and Software Availability
Raw data files for the Gene Array expression analysis have been deposited in the NCBI
Gene Expression Omnibus (accession # GSE101429).
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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HIGHLIGHTS
•

MNV-specific Trm cells during chronic infection are largely functional

•

MNV Trm cells are transcriptionally similar to inflationary T cells seen in
herpes

•

MNV-specific CD8+ T cells can be protective, but this protection wanes after
~3 days

•

CD8+ T cell ignorance in chronic MNV infection is due to poor antigen
presentation
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Figure 1. CD8+ T cell responses are generated against wild-type and mutant MNV strains

Author Manuscript

(A) Sequence of epitope P1519 in the wild-type and mutant MNV strains used in this study.
(B) RAW-264.7 cells were infected with the indicated MNV strains at a multiplicity of
infection (MOI) of 0.1 and viral load in the culture medium was measured by qPCR at the
indicated time points. Representative of 3 experiments with 2 replicates per experiment. (C)
Mice were infected orally with the indicated MNV strains and P1519-specific CD8+ T cells
enumerated on day 8 p.i. in the indicated tissues. (D) Summary of data from (C).
Representative of 3 experiments with 5 mice per group. (E) Percent of Tet+CD8+ T cells
among splenic CD44hiCD62LloCD8+ T cells responding to MNV. Error bars indicate
standard error of the mean (SEM). *Unpaired t-test (p<0.05). (F) Magnitude and (G–H)
cytokine production and coproduction by intestinal Tet+CD8+ T cells at day 41 p.i. with
MNV-CR6WT or MNV-CR6F→Y. Colors in (H) represent number of chemokines or
cytokine coproduced. (I) Shedding and (J) tissue titers of wild-type and mutant viruses
measured by qPCR. Error bars show SEM. Representative of 3 experiments with 5 mice per
group. (K) Granzyme B expression and (L) in vitro cell killing by Tet+CD8+ T cells induced
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by MNV-CW3WT or MNV-CR6F→Y. (M) P1519 sequences from stool of chronically
infected mice. See also Figures S1 and S2.
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Figure 2. Distinct transcriptional profiles of MNV-specific CD8+ T cells arise in acute versus
chronic infection
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Mice were infected orally with MNV-CW3WT or MNV-CR6F→Y and at day 30 p.i. Tet
T cells were sorted from intestinal epithelium and analyzed by microarray. (A)
Genes differentially expressed by at least 2-fold in Tet+CD8+ T cells from the 2 infections
(ANOVA P value <0.05). (B–C) Enrichment of gene sets defined by Gene Ontology (GO)
term in Tet+CD8+ T cells. Parts A–C represent 3–4 biological replicates per group, and each
biological replicate consists of pooled cells from 5 individual mice. (D) Protein expression
for several differentially expressed genes from (A). Representative of 2 independent
experiments with 4 mice per group.
+CD8+
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Figure 3. Virus-specific Trm cells are generated following infection with acute or chronic strains
of MNV
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(A–B) Expression of CD103 and CD69 on Tet+CD8+ T cells in the small intestine and colon
at day 30 p.i. with MNV-CW3WT or MNV-CR6F→Y. (C) Summary of data from (A). Error
bars show SEM. (D) Expression of CD11a and CD49d on Tet+CD8+ T cells at day 30 p.i.
with MNV-CW3WT or MNV-CR6F→Y. A–D are representative of 3 experiments with 5
mice per group. (E) MNV-CW3WT-infected mice were injected i.v. with anti-CD8α to label
blood accessible cells. Three minutes later, tissues were harvested and labeled (bloodaccessible) and unlabeled (tissue) CD8α+ T cells analyzed. The fraction of CD8+ T cells
inaccessible to i.v. staining is shown in the green gates and numbers. (F) The fraction of
CD103lo Tet+CD8+ T cells among non-circulating CD8+ T cells was enumerated. Gated on
CD8α−(green gate) cells from (E). E–F are representative of 2 experiments with 5 mice per
group. (G–I) Enrichment for Trm cell signature genes in Tet+CD8+ Tells from MNVCW3WT versus MNV-CR6F→Y infection at indicated times p.i. (J) Core enrichment genes
for (G) and (I). (K) Viral shedding and (L) titers in mice infected with MNV-CW3WT,
MNV-CR6F→Y, or both. (M) Mean fluorescence intensity of CD103 on Tet+ cells from the
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LP in (K). K–M are representative of 2 experiments with 5 mice per group. *Unpaired t-test
(p<0.05). Error bars show SEM. See also Figure S3.
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Figure 4. The transcriptional program of Tet+CD8+ T cells from chronic MNV-CR6F→Y
infection has features of effector and inflationary T cells
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Gene set enrichment of published (A) exhaustion and (B) effector CD8+ T cell signatures in
Tet+CD8+ T cells at day 30 p.i. with MNV-CR6F→Y versus MNV-CW3WT. (C) Genes
contributing simultaneously to enrichment of exhaustion and effector signatures from (A)
and (B) identified by leading edge analysis. (D) Enrichment of MCMV inflationary effector
genes in Tet+CD8+ T cells from day 30 MNV-CR6F→Y versus MNV-CW3WT infection. (E)
MNV-CR6F→Y normalized enrichment scores for the exhaustion and effector signatures
from (A–B) and (D). (F) Genes contributing to enrichment of both effector signatures from
(B) and the MCMV inflationary effector signature from (D). (G) PD-1 expression and
abundance of Tet+CD8+ T cells at day 60 p.i. with MNV-CW3WT or MNV-CR6F→Y. Part G
is representative of 2 experiments with 5 mice per group. See also Figure S4.
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Figure 5. Tet+CD8+ T cells from chronic MNV infection retain in vivo responsiveness
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(A–C) Splenic CD8+ T cells were isolated from mice chronically infected with MNVCR6F→Y (day 60 p.i.), labeled with CTV, and adoptively transferred into congenic recipients
(9×106 CD8+ T cells/recipient). Recipients were (A) naïve, or (B–C) at the indicated time
point p.i. with MNV-CW3WT or MNV-CR6F→Y. (A–C) Frequency and proliferative history
(CTV dilution) of donor Tet+CD8+ T cells 5 days post adoptive transfer in the indicated
tissues. (D) Summary of (A–C) showing percent Tet+ among donor CD8+ T cells. Error bars
show SEM. Representative of 2 independent experiments with 4 mice per group. (E–G)
Adoptive transfer was carried out as above using Thy1.1 and Thy1.2 as congenic markers.
Splenic CD8+ T cells were isolated from mice chronically infected with MNV-CR6F→Y
(day 30 p.i.), labeled with CTV, and adoptively transferred into congenic recipients (5×106
CD8+ T cells/recipient). Recipients were (E) naïve, or (F–G) at the indicated time point p.i.
with MNV-CR6F→Y or MNV-CW3WT. In (E) and (F) some recipient groups were pretreated
with anti-Thy1.1 antibody prior to transfer. Gates in green show frequency of adoptively
transferred donor cells. Plots in green show Tet staining and CTV dilution of transferred
donor cells. (H) Summary of (E–G) showing percent Tet+ among donor CD8+ T cells. Error
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bars show SEM for four mice per group. Representative of 2 independent experiments with
4 mice per group. *Unpaired t-test (p<0.05). See also Figure S5.
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Figure 6. Pre-existing Tet+CD8+ T cells can mediate protection against chronic MNV
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Mice were immunized with MNV-CW3WT or MNV-CW3Y→F and 30 days later challenged
with MNV-CR6F→Y or MNV-CR6WT. (A) Viral shedding and (B) tissue titers were
measured in challenged mice. (C) Summary of 3 independent experiments as outlined in
(A–B). (D) P1519 sequences from the proximal colon of 6 immunized mice that became
chronically infected after MNV-CR6F→Y challenge (box in (B). (E) Mice were immunized
with MNV-CW3WT, then challenged with MNV-CR6F→Y as above. The effect of CD8+ T
cell depletion on protection against MNV-CR6F→Y was tested on the indicated days post
challenge by measuring viral titers in the colon. *Unpaired t-test (p<0.05). See also Figure
S6.
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Figure 7.
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In vivo and in vitro detection of MNV by Tet+CD8+ T cells is inefficient after the initial
week of infection.
Donor mice were infected with MNV-CW3WT and 30 days later boosted with recombinant
vaccinia virus expressing epitope P1519Y (rVV519Y) to generate a large pool of MNVspecific CD8+ T cells. Donor splenocytes were labeled with CTV and adoptively transferred
into congenic recipients (10×106 splenocytes/recipient). Recipients were (A) naive or (B–F)
at the indicated time points p.i. with MNV-CW3WT or MNV-CR6F→Y. Frequency of
proliferated donor Tet+CD8+ T cells was analyzed 5 days post transfer in the LP. (G)
Summary of (A–F) showing percent Tet+ among donor CD8+ T cells in the indicated tissues.
Error bars show SEM. Representative of 2 independent experiments with 4 mice per group.
*Unpaired t-test (p<0.05). (H–J) CD8+ T cells from day 30 MNV-CR6F→Y-infected mice
(“Responders”) were labeled with CTV and incubated with total intestinal cells isolated
from congenic “Presenter” mice. Presenters were (H) naïve or (I–J) chronically infected
with MNV-CR6F→Y. In (J), intestinal preps were lysed and supplemented with APC from a
naïve mouse. Tet+CD8+ T cell responses were assessed by CTV dilution after 72 hours.
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Eight biological replicates were pooled to enable detection of rare Tet+ events. In each
biological replicate, 1×106 Responders were incubated with 5×105 Presenters. In (J), the
culture was supplemented with 1×106 naïve splenocytes. Representative of 2 independent
experiments. See also Figure S7.
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SOURCE

IDENTIFIER

Anti CD8β-PerCP-Cy5.5 (clone YTS156.7.7)

Biolegend

Cat# 126609

Anti PD-1-PE-Cy7 (clone RMP1-30)

Biolegend

Cat# 109109

Anti CD103-PacificBlue (clone 2E7)

Biolegend

Cat# 121417

Anti CD44-BV785 (clone IM7)

Biolegend

Cat# 103041

Anti CD45.2-BV785 (clone 104)

Biolegend

Cat# 109839

Anti CXCR4-BV421(clone L276F12)

Biolegend

Cat# 146511

Anti Ly6c-BV785 (clone HK1.4)

Biolegend

Cat# 128041

Anti KLRG-1-BV605 (clone 2F1)

Biolegend

Cat# 138419

Anti CD62L-BV605 (clone MEI-14)

Biolegend

Cat# 104438

Anti TNFa-PacificBlue (clone MP6-XT22)

Biolegend

Cat# 506318

Anti CD107a-AF488 (clone 1D4B)

Biolegend

Cat# 121607

Anti CD28-PE-Cy7 (clone 37.51)

Biolegend

Cat# 102126

Anti CX3CR1-PE (clone SA011F11)

Biolegend

Cat# 149006

Anti CD11a-PE (clone 2D7)

Biolegend

Cat# 101008

Anti FOXP3-PE (clone MF-14)

Biolegend

Cat# 126404

Anti CD90.1 (Thy-1.1)-BV605 (clone OX-7)

Biolegend

Cat# 202537

Anti CD25-PE-Cy5 (clone PC61)

Biolegend

Cat# 102010

Anti CD8a-PE-eF610 (clone 53.6)

eBioscience

Cat# 61-0081-80

Anti CD69-PE-Cy7 (clone H1.2F3)

eBioscience

Cat# 25-0691-82

Anti 2B4-FITC (clone eBio244F4)

eBioscience

Cat# 11-2441-82

Anti CD49b-PE-Cy5 (clone DX5)

eBioscience

Cat# 15-5971-82

Anti CD49d-FITC (clone R1-2)

eBioscience

Cat# 11-0492-81

Anti CD90.2 (Thy1.2)-FITC (clone 30-H12)

eBioscience

Cat# 11-0903-82

Anti CD27-APC-eFluor 780 (clone LG.7F9)

eBioscience

Cat# 47-0271-82

Anti CD45.1-APC-R700 (clone A20)

BD Biosciences

Cat# 565814

Anti IFN -AlexaFluor700 (clone XMG1.2)

BD Biosciences

Cat# 557998

Anti GITR-FITC (clone DTA-1)

BD Biosciences

Cat# 558139

Anti Granzyme-B-PE (clone GB11)

Invitrogen

Cat# GRB04

Anti MIP-1a-APC (clone 39624)

R&D Systems

Cat# 1C450A

Anti IL-12Rβ2-PRCP (clone 305719)

R&D Systems

Cat# FAB1959C

Anti-CD8β (Lyt 3.2) (clone 53-5.8)

Bio X Cell

Cat # BE0223

Anti-Thy1.1 (clone 19E12)

Bio X Cell

Cat # BE0214

MNV-CW3

Tomov et al., 2013

GenBank EF014462

MNV-CR6

Tomov et al., 2013

GenBank EU004676

MNV-CW3Y→F

This study

N/A
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REAGENT or RESOURCE

SOURCE

IDENTIFIER

MNV-CR6F→Y

This study

N/A

rVV519Y

This study

N/A

N/A

N/A

Deoxyribonuclease I from Bovine Pancreas

Sigma-Aldrich

Cat # D5025

Collagenase/Dispase

Roche

Cat # 11097113001

DTT (dithiothreitol)

Thermo Fisher

Cat # R0861

RPMI 1640

Corning

Cat # 15-040-CM

GemCell U.S. Origin Fetal Bovine Serum

Gemini

Cat # 100-500

UltraPure 0.5M EDTA, pH 8.0

Invitrogen

Cat # 15575-038

Penicillin-Streptomycin (10,000 U/mL)

Gibco

Cat # 151401-22

ACK Lysing Buffer

Thermo Fisher

Cat # A1049201

L-Glutamine (200mM)

Lonza

Cat # 17605E

Dulbecco’s Phosphate-Buffered Saline, 1X

Corning

Cat # 21-031-CM

Percoll

Sigma-Aldrich

Cat # P4937

RNeasy Mini Kit

Qiagen

Cat # 74106

High-Capacity cDNA Reverse Transcription Kit

Applied Biosystems

Cat # 4368814

TaqMan Gene Expression Master Mix

Applied Biosystems

Cat # 4369016

iTaq Universal SYBR Green SuperMix

Bio-Rad

Cat # 1725120

Fixation and Permeabilization Solution/Wash

BD Biosciences

Cat # 554722/554723

Brefeldin A Protein Transport Inhibitor

BD Biosciences

Cat # 555029

Monensin Protein Transport Inhibitor

BD Biosciences

Cat # 554724

Dynal CD8 Negative Isolation Kit

Invitrogen

Cat # 113.190

CellTrace CFSE Cell Proliferation Kit

Invitrogen

Cat # C34554

LIVE/DEAD Fixable Aqua Dead Stain Kit

Invitrogen

Cat # L34957

Fixation/Permeabilization Concentrate

eBioscience

Cat # 00-5123-43

Fixation/Permeabilization Diluent

eBioscience

Cat # 00-5223-56

MoGene 2.0 ST Microarray

Affymetrix

Cat # 902118

GeneChip WT PLUS Reagent Kit

Affymetrix

Cat # 902280

FuGENE-HD

Promega

Cat # E2311

NCBI GEO

GSE101429

RAW 264.7

ATCC

Cat # TIB-71

293T

ATCC

Cat # CRL-3216

143B

ATCC

Cat # CRL-8303

CV-1

ATCC

Cat # CCL-70

Biological Samples
N/A
Chemicals, Peptides, and Recombinant Proteins

Critical Commercial Assays

Deposited Data
Raw microarray data
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BSC40

ATCC

Cat # CRL-2761

C57BL/6J

Jackson Laboratory

Stock 000664

B6.SJL-Ptprca Pepcb/BoyJ

Jackson Laboratory

Stock 002014

B6.Thy1.1 (B6.PL-Thy1a/Cy)

Jackson Laboratory

Stock 000406

CW3 Y→F 1st fragment forward primer
CCCCTTGCCCCCCCAATTGGTCCC

This paper

N/A

CW3 Y→F 1st fragment reverse primer
GGCCAATTGAAAAAGGCGAGGAACCCAACTGACGACC

This paper

N/A

CW3 Y→F 2nd fragment forward primer
CCTCGCCTTTTTCAATTGGCCTCTGTGGGAAGTTTGGC

This paper

N/A

CW3 Y→F 2nd fragment reverse primer
GGAGTGAATTCTAGCGGCCGCTAGAATTCCG

This paper

N/A

CR6 F→Y 1st fragment forward primer
CCCCTTGCCCCACCCCTAGGCCCC

This paper

N/A

CR6 F→Y 1st fragment reverse primer
CGGAGGCCAATTGGTAGAGGCGGGGGACCCAGCTGACAACC

This paper

N/A

CR6 F→Y 2nd fragment forward primer
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